Effectiveness of redcore lotion in patients with vulvovaginal candidiasis: a systematic review and Meta-analysis
- PMID: 35848964
- PMCID: PMC9924725
- DOI: 10.19852/j.cnki.jtcm.2022.04.001
Effectiveness of redcore lotion in patients with vulvovaginal candidiasis: a systematic review and Meta-analysis
Abstract
Objective: To summarize and evaluate the effectiveness and safety of Redcore lotion on treating vulvovaginal candidiasis (VVC) using a systematic review and Meta-analysis of randomized controlled trials.
Methods: A systematic literature search was performed in five English and three Chinese electronic databases up to October 2019. Randomized controlled trials in the treatment for VVC were included; only studies which compared the effectiveness and safety of Redcore lotion plus miconazole with miconazole alone were included. Relative risk (RR) and 95% confidence intervals (CI) were used in the Meta-analysis.
Results: Seven studies involving 768 patients suffering from VVC were identified; 468 of the patients were pregnant women (60.9%). Combination group (Redcore lotion plus miconazole) was more effective in reduCIng symptomatic episodes of VVC than miconazole alone, with respect to cure rate (RR, 1.31; 95% CI, 1.09-1.57; P = 0.01), fungal culture negative rate (RR, 1.21; 95% CI, 1.04-1.41; P = 0.01), and effective rate (RR, 1.18; 95% CI, 1.05-1.35; P = 0.01). Subgroup analyses for pregnant women also showed that the combination group had superior outcomes with respect to VVC cure rate (RR, 1.48; 95% CI, 1.16-1.88, P < 0.01), fungal culture negative rate (RR, 1.26; 95% CI; 1.09-1.47; P < 0.01), and effective rate (RR, 1.25; 95% CI, 1.10-1.42; P < 0.01). Additionally, the observed risk of adverse events was lower in the combination medication group (RR, 0.30; 95% CI, 0.14-0.65; P < 0.01).
Conclusions: Though overall quality of individual studies was low, Redcore lotion plus miconazole can significantly improve clinical effectiveness and safety compared with miconazole alone.
Keywords: Meta-analysis; Redcore lotion; candidiasis, vulvovaginal; miconazole; systematic review.
Figures
Similar articles
-
[Clinical effect and safety of miconazole nitrate 1200 mg in treating vulvovaginal candidiasis].Zhonghua Fu Chan Ke Za Zhi. 2008 Oct;43(10):757-9. Zhonghua Fu Chan Ke Za Zhi. 2008. PMID: 19087543 Clinical Trial. Chinese.
-
Miconazole-loaded nanoparticles coated with hyaluronic acid to treat vulvovaginal candidiasis.Eur J Pharm Sci. 2023 Sep 1;188:106508. doi: 10.1016/j.ejps.2023.106508. Epub 2023 Jun 26. Eur J Pharm Sci. 2023. PMID: 37379779
-
Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis.Eur J Pharm Sci. 2018 Jan 1;111:358-375. doi: 10.1016/j.ejps.2017.10.002. Epub 2017 Oct 4. Eur J Pharm Sci. 2018. PMID: 28986195
-
Prevalence, antifungal susceptibility and etiology of vulvovaginal candidiasis in sub-Saharan Africa: a systematic review with meta-analysis and meta-regression.Med Mycol. 2022 Jul 9;60(7):myac037. doi: 10.1093/mmy/myac037. Med Mycol. 2022. PMID: 35781514
-
The Relationship Between Vulvovaginal Candidiasis and Provoked Vulvodynia: A Systematic Review.J Sex Med. 2018 Sep;15(9):1310-1321. doi: 10.1016/j.jsxm.2018.07.011. Epub 2018 Aug 23. J Sex Med. 2018. PMID: 30145093
Cited by
-
The efficacy and safety of current treatment of vulvovaginal candidiasis: An umbrella review of systematic reviews and meta-analyses.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul;398(7):7713-7720. doi: 10.1007/s00210-025-03852-2. Epub 2025 Feb 5. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39907782
-
Comparative efficacy of topical commercial Chinese polyherbal preparation for vulvovaginal candidiasis: a network meta-analysis.Front Pharmacol. 2025 Feb 3;16:1484325. doi: 10.3389/fphar.2025.1484325. eCollection 2025. Front Pharmacol. 2025. PMID: 39963237 Free PMC article.
-
Treatment of Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment Methods.J Clin Med. 2023 Aug 18;12(16):5376. doi: 10.3390/jcm12165376. J Clin Med. 2023. PMID: 37629418 Free PMC article. Review.
References
-
- Liu XP, Fan SR, Peng YT, et al.. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012. J Mycol Med 2014; 24: 106-11. - PubMed
-
- Shi XY, Yang YP, Zhang Y, et al.. Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginal candidiasis in southern China. J Med Microbiol 2015; 64: 390-3. - PubMed
-
- Fakhim H, Vaezi A, Javidnia J, et al.. Candida africana vulvovaginitis: prevalence and geographical distribution. J Mycol Med 2020; 30: 100966. - PubMed
-
- Workowski KA. Centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2015; 61: S759-62. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources